跳至主要内容
临床试验/NCT06085001
NCT06085001尚未招募不适用

Lumella is a Point of Care Blood Test Used Together With Other Blood Tests to Assess the Risk of Preeclampsia in Pregnancy in 10 Minutes. Measurements of the Biomarker.

Croydon University Hospital1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2023年11月10日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
50
试验地点
1
主要终点
can we use a bedside test -glycosylated fibronectin for the early diagnosis of pre-eclampsia

研究概览

简要总结

women with symptoms of preeclampsia from antenatal clinic or triage will be offered Lumella test along with traditional blood tests. If Lumella test is positive which will be compared with the traditional blood test results. Once 50 positive cases have been analysed the study results will be submitted to NICE.

详细描述

Pre-eclampsia is a potentially serious condition that affects pregnant women. It is usually diagnosed during routine antenatal appointments. This is based on blood pressure measurements and results of urine protein tests that are recommended at each routine antenatal visit to screen for the condition. The Triage PlGF test and the Elecsys immunoassay sFlt-1/PlGF ratio is also recommended to help rule out the condition in women presenting with suspected pre-eclampsia between 20 weeks and 34 weeks of pregnancy plus 6 days. If diagnosed with pre-eclampsia, women are usually referred to a specialist in hospital for further tests and more frequent monitoring. Depending on the severity of the condition, some women may be monitored as outpatients while others may need admission to hospital for closer monitoring or to have the condition managed in a critical care setting.

The Lumella test is based on the novel biomarker GlyFn. The company states that compared with other currently used biomarkers (such as soluble fms-like tyrosine kinase-1 [sfIT-1] and placental growth factor [PlGF] or PlGF alone), GlyFn is etiological to pre-eclampsia and maintains a linear progression throughout pregnancy. The company also claims that the test offers improved sensitivity and specificity over standard care tests. This would lead to a reduction in false positives and false negatives. The Lumella test requires a finger prick blood sample (5 microlitres). Other pre-eclampsia tests currently used in the NHS need a phlebotomy blood sample, which can be difficult to collect in some people. The test can also be transported and stored at room temperature. Other tests for pre-eclampsia need to be refrigerated and brought to room temperature before the test can be done. The Lumella test may improve patient experience and allow a more rapid turnaround time for results. The company states that Lumella is currently the only test that can be done within 10 minutes at room temperature.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

性别
Female
接受健康志愿者

入选标准

  • If they can speak English
  • Can give informed consent
  • Has symptoms of Preeclampsia

排除标准

  • Can't speak English
  • Does not want to participate

结局指标

主要结局

can we use a bedside test -glycosylated fibronectin for the early diagnosis of pre-eclampsia

时间窗: 6 months

Does the test work?

次要结局

  • Is glycosylated fibronectin better than placental growth factor or traditional blood tests(6 months)

研究者

发起方
Croydon University Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Bini Ajay

Consultant Obstetrician and Gynaecologist

Croydon University Hospital

研究点 (1)

Loading locations...

相似试验